ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: () Report Updated: May 04, 2016 | Print This Page

Get more stock ratings by Louis Navellier

(ETRM)

Rating: Volatility:
Total Grade: Industry:
Competitors:

Stock Analysis

Rating: Monthly View

A
B
C
D
F
May June July August September October November December January February March April

Rating: Weekly View

This Week: down no change
Last Week: same no change
Two Weeks Ago: up no change
service keys

© quotemedia

Company Profile

EnteroMedics Inc., a medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. The company’s proprietary neuroblocking technology is designed to intermittently block the vagus nerve using electrical impulses. It develops the Maestro Rechargeable System, which is used to limit the expansion of the stomach, control hunger sensations between meals, reduce the frequency and intensity of stomach contractions, and produce a feeling of early and prolonged fullness. The company is evaluating the Maestro System in human clinical trials in the United States, Australia, and Mexico. It has collaboration with Mayo Clinic for the development and testing of products for the treatment of obesity. The company was formerly known as Beta Medical, Inc. and changed its name to EnteroMedics Inc. in 2003. EnteroMedics Inc. was founded in 2002 and is headquartered in St. Paul, Minnesota.